On Wednesday, Shares of CEMEX, S.A.B. de C.V. (NYSE:CX), showed no change in percentage to $8.08.
CEMEX, S.A.B., declared that it has signed a contract for the sale of its operations in Austria and Hungary to the Rohrdorfer Group for about €160.1 million.
The Austrian operations comprise of 24 aggregate quarries (about 6.47 million metric tons of aggregates sold in 2014) and 34 ready-mix plants (about 1.60 million cubic meters of ready-mix sold in 2014). CEMEX’s operations in Austria had net sales of about U.S.$241 million in 2014.
The Hungarian operations being divested comprise of 5 aggregate quarries (about 1.36 million metric tons of aggregates sold in 2014) and 34 ready-mix plants (about 0.46 million cubic meters of ready-mix sold in 2014). CEMEX’s operations in Hungary had net sales of about U.S.$47 million in 2014.
CEMEX, S.A.B. de C.V., a building materials company, produces, markets, distributes, and sells cement, ready-mix concrete, aggregates, and other construction materials in Mexico, the United States, Northern Europe, the Mediterranean, South America, the Caribbean, and Asia.
Shares of AbbVie Inc. (NYSE:ABBV), inclined 0.73% to $68.75, during its last trading session.
AbbVie declared that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or formerly untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis. The open-label study evaluated the efficacy and safety of venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche.
Data from this study will be presented at an forthcoming medical conference and will serve as the pivotal registration data for applications to the FDA, EMA and other health authorities. The safety profile was similar to previous studies and no unpredictable safety signals were stated for venetoclax.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Finally, Spectra Energy Corp. (NYSE:SE), ended its last trade with 2.67% gain, and closed at $30.79, as Oil ended up on Wednesday as a weaker dollar and lower U.S. crude stockpiles offered a modest bounce off six-year lows hit the previous session, when worries about China’s plummeting currency and economic slowdown deflated prices, according to Reuters.
Concerns that U.S. inventories could build again from higher crude imports and refinery outages kept a lid on the rebound.
U.S. crude futures CLc1 settled up 22 cents, or 0.5 percent, at $43.30 a barrel, after gaining almost 80 cents at the session high. The market lost $1.88, or more than 4 percent, on Tuesday, settling at $43.08 a barrel, its lowest since March 2009. Reuters Reports
Spectra Energy Corp, through its auxiliaries, owns and operates a portfolio of natural gas-related energy assets in North America.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
